From Public Citizen: Januvia (scientific name sitagliptin), a new drug designed to improve blood sugar control in patients with type 2 diabetes, should not be used because the drug’s long-term safety is still unknown.
Clinical study patients who were given Januvia experienced an increase in the chemical creatinine, which is found in the blood. Increases in creatinine are often an early indicator of kidney problems. Because the drug is new, more serious adverse effects may not become apparent until the drug is used by a large number of patients. Public Citizen advises consumers not to take the drug until after it has been on the market for seven years – in this case, until 2014 – without exhibiting significant health risks.
What is notable is that P.C. suggests that people with Type 2 Diabetes should wait seven years before taking Januvia.